0001209191-20-005034.txt : 20200127
0001209191-20-005034.hdr.sgml : 20200127
20200127171503
ACCESSION NUMBER: 0001209191-20-005034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200123
FILED AS OF DATE: 20200127
DATE AS OF CHANGE: 20200127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paul Robert
CENTRAL INDEX KEY: 0001757964
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38792
FILM NUMBER: 20550624
MAIL ADDRESS:
STREET 1: C/O ALECTOR, INC.
STREET 2: 151 OYSTER POINT BLVD., #300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Alector, Inc.
CENTRAL INDEX KEY: 0001653087
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462702363
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD., SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-231-5660
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD., SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Alector LLC
DATE OF NAME CHANGE: 20150915
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-23
0
0001653087
Alector, Inc.
ALEC
0001757964
Paul Robert
C/O ALECTOR, INC.
131 OYSTER POINT BLVD, SUITE 600
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
2020-01-23
4
M
0
6000
8.16
A
279719
D
Common Stock
2020-01-23
4
S
0
5401
24.22
D
274318
D
Common Stock
2020-01-23
4
S
0
599
25.22
D
273719
D
Stock Option (right to buy)
8.16
2020-01-23
4
M
0
6000
0.00
D
2028-07-01
Common Stock
6000
338000
D
The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.00 to $24.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.21 to $25.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
/s/ Stephanie Yonker, attorney-in-fact
2020-01-27